
Join to View Full Profile
15245 Shady Grove RoadSuite 455Rockville, MD 20850
Phone+1 240-268-5300
Dr. Benaim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of South Florida MorsaniResidency, Pediatrics, 1990 - 1993
- Central University of VenezuelaClass of 1987
Clinical Trials
- Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2008 Sep 01
Publications & Presentations
PubMed
- 4 citationsA multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxe...Hani M. Babiker, Peter J. Schlegel, Lee G. Hicks, Andrea J. Bullock, Nafisa Burhani
Investigational New Drugs. 2021-08-21 - 19 citationsRX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.Beatrice Balboni, Btissame El Hassouni, Richard J. Honeywell, Dzjemma Sarkisjan, Elisa Giovannetti
Expert Opinion on Investigational Drugs. 2019-03-16 - 16 citationsSPONTANEOUS REMISSION IN MONOSOMY 7 MYELODYSPLASTIC SYNDROMEEly Benaim, Eva Hvizdala, Peter Papenhausen, Lynn C. Moscinski
British Journal of Haematology. 2008-03-12
Press Mentions
- Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian CancerMarch 23rd, 2022
- Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual MeetingNovember 15th, 2021
- 2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed GlioblastomaNovember 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: